Unidad de Investigación Médica en Inmunología, UMAE, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico.
División de Programas Educativos de la Coordinación de Educación en Salud, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico.
J Immunol Res. 2020 Jun 27;2020:5692829. doi: 10.1155/2020/5692829. eCollection 2020.
Interleukin- (IL-) 17 is increased in acute myocardial infarction (AMI) and plays a key role in inflammatory diseases through its involvement in the activation of leukocytes. Here, we describe for the first time the effect of IL-17 in the migration and activation of monocyte subsets in patients during ST-segment elevation myocardial infarction (STEMI) and post-STEMI. We analyzed the circulating levels of IL-17 in patient plasma. A gradual increase in IL-17 was found in STEMI and post-STEMI patients. Additionally, IL-17 had a powerful effect on the recruitment of CD14CD16/CD14CD16 monocytes derived from patients post-STEMI compared with the monocytes from patients with STEMI, suggesting that IL-17 recruits monocytes with inflammatory activity post-STEMI. Furthermore, IL-17 increased the expression of TLR4 on CD14 CD16 and CD14CD16/CD14CD16 monocytes post-STEMI and might enhance the response to danger-associated molecular patterns post-STEMI. Moreover, IL-17 induced secretion of IL-6 from CD14CD16 and CD14CD16/CD14CD16 monocytes both in STEMI and in post-STEMI, which indicates that IL-17 has an effect on the secretion of proinflammatory cytokines from monocytes during STEMI and post-STEMI. Overall, we demonstrate that in STEMI and post-STEMI, IL-17 is increased and induces the migration and activation of monocyte subsets, possibly contributing to the inflammatory response through TLR4 and IL-6 secretion.
白细胞介素- (IL-) 17 在急性心肌梗死 (AMI) 中增加,并通过其参与白细胞的激活在炎症性疾病中发挥关键作用。在这里,我们首次描述了白细胞介素-17 在 ST 段抬高型心肌梗死 (STEMI) 和 STEMI 后患者单核细胞亚群迁移和激活中的作用。我们分析了患者血浆中白细胞介素-17 的循环水平。在 STEMI 和 STEMI 后患者中发现白细胞介素-17 逐渐增加。此外,与 STEMI 患者的单核细胞相比,白细胞介素-17 对源自 STEMI 后患者的 CD14CD16/CD14CD16 单核细胞的募集具有强大作用,表明白细胞介素-17 在 STEMI 后募集具有炎症活性的单核细胞。此外,白细胞介素-17 增加了 CD14 CD16 和 CD14CD16/CD14CD16 单核细胞上 TLR4 的表达,并且可能在 STEMI 后增强对危险相关分子模式的反应。此外,白细胞介素-17 诱导 CD14CD16 和 CD14CD16/CD14CD16 单核细胞在 STEMI 和 STEMI 后均分泌白细胞介素-6,这表明白细胞介素-17 对 STEMI 和 STEMI 期间单核细胞促炎细胞因子的分泌有影响。总体而言,我们证明在 STEMI 和 STEMI 后,白细胞介素-17 增加并诱导单核细胞亚群的迁移和激活,可能通过 TLR4 和白细胞介素-6 的分泌促进炎症反应。